2025
Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus
Xu H, Aparicio C, Wats A, Araujo B, Pitzer V, Warren J, Shapiro E, Niccolai L, Weinberger D, Oliveira C. Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus. JAMA Network Open 2025, 8: e250380. PMID: 40063022, PMCID: PMC11894488, DOI: 10.1001/jamanetworkopen.2025.0380.Peer-Reviewed Original ResearchConceptsRSV-positive casesCase-control studyRSV infectionLRTI-associated hospitalizationsWeeks postimmunizationLong-acting monoclonal antibodiesTest-negative case-control studyClinical settingRespiratory syncytial virusMultivariate logistic regressionYale New Haven Health SystemRSV diseaseEmergency department dataState immunization registryRSV seasonSyncytial virusNirsevimabPolymerase chain reactionClinical trialsLRTIInfantsPotential confoundersMonoclonal antibodiesBroader outcomesDisease severity
2012
Understanding Reduced Rotavirus Vaccine Efficacy in Low Socio-Economic Settings
Lopman BA, Pitzer VE, Sarkar R, Gladstone B, Patel M, Glasser J, Gambhir M, Atchison C, Grenfell BT, Edmunds WJ, Kang G, Parashar UD. Understanding Reduced Rotavirus Vaccine Efficacy in Low Socio-Economic Settings. PLOS ONE 2012, 7: e41720. PMID: 22879893, PMCID: PMC3412858, DOI: 10.1371/journal.pone.0041720.Peer-Reviewed Original ResearchConceptsLow socio-economic settingRotavirus vaccine efficacyVaccine efficacyRotavirus vaccineSevere diseaseNatural infectionImmunogenicity of vaccinationReduced vaccine efficacySevere rotavirus gastroenteritisReduced efficacyClinical trial resultsLow SES populationsRotavirus gastroenteritisVaccine performanceVaccination programImmune responseEpidemiological factorsVaccineVaccinationTrial resultsInfectionSES populationsEfficacyReduced protectionEfficacy declines
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply